IMSA101

DRUG5 trials

Sponsors

ImmuneSensor Therapeutics Inc., University of Texas Southwestern Medical Center

Conditions

Metastatic Renal Cell Carcinoma ( mRCC)OligoProgressive Metastatic DiseaseOligometastatic DiseaseOligoprogressiveSolid Tumor, Adult

Phase 1

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

CompletedNCT04020185

ImmuneSensor Therapeutics Inc.Solid Tumor, Adult

Start: 2019-09-23End: 2023-09-15Updated: 2024-12-11

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Active, not recruitingNCT06026254

ImmuneSensor Therapeutics Inc.Solid Tumor, Adult

Start: 2023-09-15End: 2025-09-30Target: 2Updated: 2024-11-18

Phase 2

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

TerminatedNCT05846659

ImmuneSensor Therapeutics Inc.Oligoprogressive

Start: 2023-07-07End: 2024-11-20Updated: 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC

TerminatedNCT05846646

ImmuneSensor Therapeutics Inc.Oligometastatic Disease

Start: 2023-06-28End: 2024-09-16Updated: 2025-10-20

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

RecruitingNCT06601296

University of Texas Southwestern Medical CenterMetastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease

Start: 2025-04-01End: 2028-10-31Target: 15Updated: 2025-11-12

Related Papers

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies

Journal for ImmunoTherapy of Cancer2025-06-019 citations

Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.

Journal of Clinical Oncology2024-06-014 citations